Cannabinoids

Subject Index 759

BAY 38-7271 8, 17
Bezold-Jarisch reflex 614, 615, 618
binding seeassays
bioassay seeassays
birds 290
body temperature 11–12, 561, 693
BOLD 431
brachial plexus injury 731
bradycardia 345,346,348,601,603,
606, 615
brain areas 705
amygdala 705
cerebellum 705
hippocampus 705
brain development 643–645, 647–
652
axonalelongation 643,646,649,
652
cell migration 643, 646, 652
cellproliferation 643,646,652
myelogenesis 643,646,647,652
neurogenesis 646
synaptogenesis 643, 646, 652
brainstem
area postrema 316
dorsal motor nucleus of the va-
gus 316
nucleusofthesolitarytract 316
subnucleus gelatinosus 316
breast cancer cells 410
Brucella suis 399, 413

(^11) C 429
c-fos 62
C. elegans 286, 287, 289, 291–293
C. parvum 397
Ca2+fluxes 58
Caenorhabditis elegans 285
calbindin 575, 590
calcitoningene-relatedpeptide(CGRP)
347, 608, 609, 613, 614
calcium 375
calcium channels 3, 11, 22, 26, 34,
36, 37, 329, 349
calcium-activated potassium (BKCa)
channel 611
calmodulin kinase 62
calretinin 575, 591
cancer 574, 576, 589, 628
patients 734
Candida albicans 403
candidiasis 404
cannabidiol (CBD) 19, 26, 34–38,
235, 601, 609, 610, 657, 723,
724, 726–728, 731, 734, 737,
738, 745, 746, 748, 749
cannabinoid ligands during develop-
ment 645, 647, 652
2-arachidonoylglycerol (2-AG)
645, 647
anandamide (AEA) 645, 647
cannabinoid receptor
constitutiveactivity 23,38,39,
95–99, 248, 249, 252, 328,
353
cross-talk, 4, 38, 39, 457, 564
desensitization, 54, 67, 68, 82,
96, 99,101, 102, 694–696,
704
gene,82,83,87,88,100,103,118,
134, 290, 291–294, 408, 636,
704
in the basal ganglia, 484
internalization, 82, 96, 101–102,
516, 695
knockout mice, 12, 82, 99, 103–
105, 117–137, 393, 488, 560
oligomerization, 38
probes, 209, 232, 233
cannabinoid receptor agonists

see∆^9 -tetrahydrocannabinol

(THC)

seeACEA

seeACPA

seeAM1241

seecannabinol

seeCP55940

seeHU-210

seeHU-308

seeJWH-015

seeJWH-133

seelevonantradol (L-nantradol)